INTRODUCTION

the COVID-19 pandemic has already caused hundreds of thousands of deaths and there is no specific treatment.

OBJECTIVE

we intend to answer whether, in patients with severe pneumonia caused by COVID-19, treatment with chloroquine/hydroxychloroquine compared to the usual support treatment reduces the risk of mortality, the time for clinical improvement, and to evaluate its safety.

METHODS

An independent multidisciplinary team was formed to conduct a health technology assessment including a systematic review and meta-analysis. Studies published in Spanish, Portuguese and English until June 2020 were included.

RESULTS

169 studies were identified. 6 were included in the qualitative review, 4 in the meta-analysis and 14 as other documents. In the quantitative analysis we found a relative risk (RR) of 1.52, 95% confidence interval (95%CI) of 1.14-2.04 for clinical or tomographic improvement before 14 days, with low certainty in the evidence. Adverse events at 7 and 28 days had a RR of 2.22 (95%CI: 0.45-10.91) with low certainty of evidence. The recommendations of scientific societies and health authorities were heterogeneous.

CONCLUSIONS

the evidence found is from low to very low confidence, therefore any estimated result is highly uncertain. On the other hand, no data were found on mortality or on the reduction of time in mechanical respiratory support, so more studies are required that include these outcomes. The informed consent process is essential, whether it is used in the context of an investigation or as an off-label use in routine practice.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )